Please assess the completion status of the following clinical trial:

Trial Title: Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age and older~2. Implantation with HeartMate II® or HeartWare®, LVAD at Barnes Jewish Hospital~Exclusion Criteria:~1. Unable to receive heparin-based therapy~2. Hypercoagulable disorders \[factor V Leiden, Antithrombin deficiency, Protein C deficiency, Antiphospholipid antibodies or other thrombophilia\]~3. Incarceration~4. Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- aPTT nomogram (Type: ACTIVE_COMPARATOR): aPTT guided heparin management
- Anti-factor Xa nomogram (Type: EXPERIMENTAL): Anti-factor Xa guided heparin management

Based on this trial design, predict the completion outcome and termination type (if applicable).